Search

Your search keyword '"Pokushalov, Evgeny"' showing total 454 results
Start Over Author "Pokushalov, Evgeny"
454 results on '"Pokushalov, Evgeny"'

2. Effect of Methylfolate, Pyridoxal-5′-Phosphate, and Methylcobalamin (SolowaysTM) Supplementation on Homocysteine and Low-Density Lipoprotein Cholesterol Levels in Patients with Methylenetetrahydrofolate Reductase, Methionine Synthase, and Methionine Synthase Reductase Polymorphisms: A Randomized Controlled Trial

Author

Pokushalov, Evgeny, primary, Ponomarenko, Andrey, additional, Bayramova, Sevda, additional, Garcia, Claire, additional, Pak, Inessa, additional, Shrainer, Evgenya, additional, Ermolaeva, Marina, additional, Kudlay, Dmitry, additional, Johnson, Michael, additional, and Miller, Richard, additional

Published
2024
Full Text
View/download PDF

5. Incidence and predictors of 2-year mortality following percutaneous left atrial appendage occlusion in the EWOLUTION trial.

Author

Aarnink, Errol W, Ince, Hueseyin, Kische, Stephan, Pokushalov, Evgeny, Schmitz, Thomas, Schmidt, Boris, Gori, Tommaso, Meincke, Felix, Protopopov, Alexey Vladimir, Betts, Timothy, Mazzone, Patrizio, Grygier, Marek, Sievert, Horst, Potter, Tom De, Vireca, Elisa, Stein, Kenneth, Bergmann, Martin W, and Boersma, Lucas V A

Abstract

Aims Sufficient survival time following left atrial appendage occlusion (LAAO) is essential for ensuring the efficacy and cost-effectiveness of this strategy for stroke prevention. Understanding prognostic factors for early mortality after LAAO could optimize patient selection. In the current study, we perform an in-depth analysis of 2-year mortality after LAAO, focusing particularly on potential predictors. Methods and results The EWOLUTION registry is a real-world cohort comprising 1020 patients that underwent LAAO. Endpoint definitions were pre-specified, and death was categorized as cardiovascular, non-cardiovascular, or unknown origin. Mortality rates were calculated from Kaplan–Meier estimates. Baseline characteristics significantly associated with death in univariate Cox regression analysis were incorporated into the multivariate analysis. All multivariate predictors were included in a risk model. Two-year mortality rate was 16.4% [confidence interval (CI): 14.0–18.7%], with 50% of patients dying from a non-cardiovascular cause. Multivariate baseline predictors of 2-year mortality included age [hazard ratio (HR) 1.05, CI: 1.03–1.08, per year increase], heart failure (HR 1.73, CI: 1.24–2.41), vascular disease (HR 1.47, CI: 1.05–2.05), valvular disease (HR 1.63, CI: 1.15–2.33), abnormal liver function (HR 1.80, CI: 1.02–3.17), and abnormal renal function (HR 1.58, CI: 1.10–2.27). Mortality rate exhibited a gradual rise as the number of risk factors increased, reaching 46.1% in patients presenting with five or six risk factors. Conclusion One in six patients died within 2 years after LAAO. We identified six independent predictors of mortality. When combined, this model showed a gradual increase in mortality rate with a growing number of risk factors, which may guide appropriate patient selection for LAAO. Clinical trial registration The original EWOLUTION registry was registered at clinicaltrials.gov under identifier NCT01972282. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Efficacy of AI-Guided (GenAISTM) Dietary Supplement Prescriptions versus Traditional Methods for Lowering LDL Cholesterol: A Randomized Parallel-Group Pilot Study.

Author

Pokushalov, Evgeny, Ponomarenko, Andrey, Smith, John, Johnson, Michael, Garcia, Claire, Pak, Inessa, Shrainer, Evgenya, Kudlay, Dmitry, Bayramova, Sevda, and Miller, Richard

Abstract

Emerging evidence suggests that personalized dietary supplement regimens can significantly influence lipid metabolism and cardiovascular risk. The efficacy of AI-guided dietary supplement prescriptions, compared with standard physician-guided prescriptions, remains underexplored. In a randomized, parallel-group pilot study, 70 patients aged 40-75 years with LDL-C levels between 70 and 190 mg/dL were enrolled. Participants were randomized to receive either AI-guided dietary supplement prescriptions or standard physician-guided prescriptions for 90 days. The primary endpoint was the percent change in LDL-C levels. Secondary endpoints included changes in total cholesterol, HDL-C, triglycerides, and hsCRP. Supplement adherence and side effects were monitored. Sixty-seven participants completed the study. The AI-guided group experienced a 25.3% reduction in LDL-C levels (95% CI: -28.7% to -21.9%), significantly greater than the 15.2% reduction in the physician-guided group (95% CI: -18.5% to -11.9%; p < 0.01). Total cholesterol decreased by 15.4% (95% CI: -19.1% to-11.7%) in the AI-guided group compared with 8.1% (95% CI:-11.5% to -4.7%) in the physician-guided group (p < 0.05). Triglycerides were reduced by 22.1% (95% CI: -27.2% to -17.0%) in the AI-guided group versus 12.3% (95% CI: -16.7% to -7.9%) in the physician-guided group (p < 0.01). HDL-C and hsCRP changes were not significantly different between groups. The AI-guided group received a broader variety of supplements, including plant sterols, omega-3 fatty acids, red yeast rice, coenzyme Q10, niacin, and fiber supplements. Side effects were minimal and comparable between groups. AI-guided dietary supplement prescriptions significantly reduce LDL-C and triglycerides more effectively than standard physician-guided prescriptions, highlighting the potential for AI-driven personalization in managing hypercholesterolemia. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Effect of Methylfolate, Pyridoxal-5′-Phosphate, and Methylcobalamin (Soloways TM) Supplementation on Homocysteine and Low-Density Lipoprotein Cholesterol Levels in Patients with Methylenetetrahydrofolate Reductase, Methionine Synthase, and Methionine Synthase Reductase Polymorphisms: A Randomized Controlled Trial

Author

Pokushalov, Evgeny, Ponomarenko, Andrey, Bayramova, Sevda, Garcia, Claire, Pak, Inessa, Shrainer, Evgenya, Ermolaeva, Marina, Kudlay, Dmitry, Johnson, Michael, and Miller, Richard

Abstract

Exploring the link between genetic polymorphisms in folate metabolism genes (MTHFR, MTR, and MTRR) and cardiovascular disease (CVD), this study evaluates the effect of B vitamin supplements (methylfolate, pyridoxal-5′-phosphate, and methylcobalamin) on homocysteine and lipid levels, potentially guiding personalized CVD risk management. In a randomized, double-blind, placebo-controlled trial, 54 patients aged 40–75 with elevated homocysteine and moderate LDL-C levels were divided based on MTHFR, MTR, and MTRR genetic polymorphisms. Over six months, they received either a combination of methylfolate, P5P, and methylcobalamin, or a placebo. At the 6 months follow-up, the treatment group demonstrated a significant reduction in homocysteine levels by 30.0% (95% CI: −39.7% to −20.3%) and LDL-C by 7.5% (95% CI: −10.3% to −4.7%), compared to the placebo (p < 0.01 for all). In the subgroup analysis, Homozygous Minor Allele Carriers showed a more significant reduction in homocysteine levels (48.3%, 95% CI: −62.3% to −34.3%, p < 0.01) compared to mixed allele carriers (18.6%, 95% CI: −25.6% to −11.6%, p < 0.01), with a notable intergroup difference (29.7%, 95% CI: −50.7% to −8.7%, p < 0.01). LDL-C levels decreased by 11.8% in homozygous carriers (95% CI: −15.8% to −7.8%, p < 0.01) and 4.8% in mixed allele carriers (95% CI: −6.8% to −2.8%, p < 0.01), with a significant between-group difference (7.0%, 95% CI: −13.0% to −1.0%, p < 0.01). Methylfolate, P5P, and methylcobalamin supplementation tailored to genetic profiles effectively reduced homocysteine and LDL-C levels in patients with specific MTHFR, MTR, and MTRR polymorphisms, particularly with homozygous minor allele polymorphisms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Evaluating the Impact of Omega-3 Fatty Acid (SolowaysTM) Supplementation on Lipid Profiles in Adults with PPARG Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial

Author

Pokushalov, Evgeny, primary, Ponomarenko, Andrey, additional, Bayramova, Sevda, additional, Garcia, Claire, additional, Pak, Inessa, additional, Shrainer, Evgenya, additional, Voronina, Elena, additional, Sokolova, Ekaterina, additional, Johnson, Michael, additional, and Miller, Richard, additional

Published
2023
Full Text
View/download PDF

14. The Impact of Glucomannan, Inulin, and Psyllium Supplementation (Soloways TM) on Weight Loss in Adults with FTO, LEP, LEPR, and MC4R Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial.

Author

Pokushalov, Evgeny, Ponomarenko, Andrey, Garcia, Claire, Pak, Inessa, Shrainer, Evgenya, Seryakova, Mariya, Johnson, Michael, and Miller, Richard

Abstract

This study aimed to determine the impact of a fiber supplement on body weight and composition in individuals with obesity with specific genetic polymorphisms. It involved 112 adults with obesity, each with at least one minor allele in the FTO, LEP, LEPR, or MC4R polymorphism. Participants were randomized to receive either a fiber supplement (glucomannan, inulin, and psyllium) or a placebo for 180 days. The experimental group showed significant reductions in body weight (treatment difference: −4.9%; 95% CI: −6.9% to −2.9%; p < 0.01) and BMI (treatment difference: −1.4 kg/m2; 95% CI: −1.7 to −1.2; p < 0.01) compared to placebo. Further significant decreases in fat mass (treatment difference: −13.0%; 95% CI: −14.4 to −11.7; p < 0.01) and visceral fat rating (treatment difference: −1.3; 95% CI: −1.6 to −1.0; p < 0.01) were noted. Homozygous minor allele carriers experienced greater decreases in body weight (treatment difference: −3.2%; 95% CI: −4.9% to −1.6%; p < 0.01) and BMI (treatment difference: −1.2 kg/m2; 95% CI: −2.0 to −0.4; p < 0.01) compared to heterozygous allele carriers. These carriers also had a more significant reduction in fat mass (treatment difference: −9.8%; 95% CI: −10.6 to −9.1; p < 0.01) and visceral fat rating (treatment difference: −0.9; 95% CI: −1.3 to −0.5; p < 0.01). A high incidence of gastrointestinal events was reported in the experimental group (74.6%), unlike the placebo group, which reported no side effects. Dietary supplementation with glucomannan, inulin, and psyllium effectively promotes weight loss and improves body composition in individuals with obesity, particularly those with specific genetic polymorphisms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Evaluating the Impact of Omega-3 Fatty Acid (Soloways TM) Supplementation on Lipid Profiles in Adults with PPARG Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial.

Author

Pokushalov, Evgeny, Ponomarenko, Andrey, Bayramova, Sevda, Garcia, Claire, Pak, Inessa, Shrainer, Evgenya, Voronina, Elena, Sokolova, Ekaterina, Johnson, Michael, and Miller, Richard

Abstract

Emerging evidence suggests that PPARG gene polymorphisms may influence lipid metabolism and cardiovascular risk, with omega-3 fatty acids proposed to modulate these effects. This study aims to assess the effects of fish oil supplementation on cardiovascular markers among adults with PPARG gene polymorphisms in a randomized, double-blind, placebo-controlled trial. A cohort of 102 patients with LDL-C 70–190 mg/dL was randomized to receive either 2000 mg of omega-3 fatty acids or a placebo daily for 90 days. In the omega-3 group with PPARG polymorphisms, LDL-C was reduced by 15.4% (95% CI: −19.8% to −11.0%), compared with a 2.6% decrease in the placebo group (95% CI: −4.1% to −1.1%; p < 0.01). In the omega-3 group without PPARG polymorphisms, LDL-C was reduced by 3.7% (95% CI: −6.9% to −0.6%), not significantly different from the placebo group's reduction of 2.9% (95% CI: −5.1% to −0.8%; p = 0.28). The reduction in LDL-C was notably 11.7% greater in those with PPARG polymorphisms than in those without (95% CI: −19.3% to −4.0%; p < 0.01). Triglycerides decreased by 21.3% in omega-3 recipients with PPARG polymorphisms (95% CI: −26.5% to −16.2%; p < 0.01), with no significant changes in HDL-C, total cholesterol, or hsCRP levels in any groups. Minor allele frequencies and baseline characteristics were comparable, ensuring a balanced genetic representation. Omega-3 fatty acids significantly reduce LDL-C and triglycerides in carriers of PPARG polymorphisms, underlining the potential for genetic-driven personalization of cardiovascular interventions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Impact of Left Ventricular Function and Heart Failure Symptoms on Outcomes Post Ablation of Atrial Fibrillation in Heart Failure: CASTLE-AF Trial

Author

Sohns, Christian, Zintl, Konstantin, Zhao, Yan, Dagher, Lilas, Andresen, Dietrich, Siebels, Jürgen, Wegscheider, Karl, Sehner, Susanne, Boersma, Luca, Merkely, Béla, Pokushalov, Evgeny, Sanders, Prashanthan, Schunkert, Heribert, Bänsch, Dietmar, Mahnkopf, Christian, Brachmann, Johannes, and Marrouche, Nassir F.

Published
2020
Full Text
View/download PDF

22. Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology: Final 2-Year Outcome Data of the EWOLUTION Trial Focusing on History of Stroke and Hemorrhage

Author

Boersma, Lucas V., Ince, Hueseyin, Kische, Stephan, Pokushalov, Evgeny, Schmitz, Thomas, Schmidt, Boris, Gori, Tommaso, Meincke, Felix, Protopopov, Alexey Vladimir, Betts, Timothy, Mazzone, Patrizio, Foley, David, Grygier, Marek, Sievert, Horst, De Potter, Tom, Vireca, Elisa, Stein, Kenneth, Bergmann, Martin W., Al Nooryani, Arif, Fiedler, Thomas, Senatore, Gaetano, Brigadeau, François, Defaye, Pascal, Teiger, Emmanuel, Bonnet, Jean-Louis, Wald, Christof, Szili-Torok, Tamas, Tschishow, Wladimir, Crossland, David, Vahanian, Alec, Cruz-Gonzalez, Ignacio, Thambo, Jean-Benoit, Al Smadi, Faisal, Mudra, Harald, Molitoris, Robin, Folkeringa, Richard, Stevenhagen, Yorick, Gras, Daniel, Tamburino, Corrado, Molon, Giulio, Spence, Mark, Infante Oliveira, Eduardo, Merkulov, Evgeny, Sukiennik, Adam, Wong, Tom, Busch, Mathias, Boldt, Leif-Hendrik, Nickenig, Georg, and Neef, Martin

Published
2019
Full Text
View/download PDF

24. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary

Author

Calkins, Hugh, Hindricks, Gerhard, Cappato, Riccardo, Kim, Young-Hoon, Saad, Eduardo B., Aguinaga, Luis, Akar, Joseph G., Badhwar, Vinay, Brugada, Josep, Camm, John, Chen, Peng-Sheng, Chen, Shih-Ann, Chung, Mina K., Nielsen, Jens Cosedis, Curtis, Anne B., Wyn Davies, D., Day, John D., d’Avila, André, de Groot, N.M.S. (Natasja), Di Biase, Luigi, Duytschaever, Mattias, Edgerton, James R., Ellenbogen, Kenneth A., Ellinor, Patrick T., Ernst, Sabine, Fenelon, Guilherme, Gerstenfeld, Edward P., Haines, David E., Haissaguerre, Michel, Helm, Robert H., Hylek, Elaine, Jackman, Warren M., Jalife, Jose, Kalman, Jonathan M., Kautzner, Josef, Kottkamp, Hans, Kuck, Karl Heinz, Kumagai, Koichiro, Lee, Richard, Lewalter, Thorsten, Lindsay, Bruce D., Macle, Laurent, Mansour, Moussa, Marchlinski, Francis E., Michaud, Gregory F., Nakagawa, Hiroshi, Natale, Andrea, Nattel, Stanley, Okumura, Ken, Packer, Douglas, Pokushalov, Evgeny, Reynolds, Matthew R., Sanders, Prashanthan, Scanavacca, Mauricio, Schilling, Richard, Tondo, Claudio, Tsao, Hsuan-Ming, Verma, Atul, Wilber, David J., and Yamane, Teiichi

Published
2017
Full Text
View/download PDF

27. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation

Author

Calkins, Hugh, Hindricks, Gerhard, Cappato, Riccardo, Kim, Young-Hoon, Saad, Eduardo B, Aguinaga, Luis, Akar, Joseph G, Badhwar, Vinay, Brugada, Josep, Camm, John, Chen, Peng-Sheng, Chen, Shih-Ann, Chung, Mina K, Cosedis Nielsen, Jens, Curtis, Anne B, Davies, D Wyn, Day, John D, d’Avila, André, (Natasja) de Groot, N M S, Di Biase, Luigi, Duytschaever, Mattias, Edgerton, James R, Ellenbogen, Kenneth A, Ellinor, Patrick T, Ernst, Sabine, Fenelon, Guilherme, Gerstenfeld, Edward P, Haines, David E, Haissaguerre, Michel, Helm, Robert H, Hylek, Elaine, Jackman, Warren M, Jalife, Jose, Kalman, Jonathan M, Kautzner, Josef, Kottkamp, Hans, Kuck, Karl Heinz, Kumagai, Koichiro, Lee, Richard, Lewalter, Thorsten, Lindsay, Bruce D, Macle, Laurent, Mansour, Moussa, Marchlinski, Francis E, Michaud, Gregory F, Nakagawa, Hiroshi, Natale, Andrea, Nattel, Stanley, Okumura, Ken, Packer, Douglas, Pokushalov, Evgeny, Reynolds, Matthew R, Sanders, Prashanthan, Scanavacca, Mauricio, Schilling, Richard, Tondo, Claudio, Tsao, Hsuan-Ming, Verma, Atul, Wilber, David J, Yamane, Teiichi, Blomström-Lundqvist, Carina, De Paola, Angelo A V, Kistler, Peter M, Lip, Gregory Y H, Peters, Nicholas S, Pisani, Cristiano F, Raviele, Antonio, Saad, Eduardo B, Satomi, Kazuhiro, Stiles, Martin K, and Willems, Stephan

Published
2018
Full Text
View/download PDF

33. Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data

Author

Gyöngyösi, Mariann, primary, Pokushalov, Evgeny, additional, Romanov, Aleksander, additional, Perin, Emerson, additional, Hare, Joshua M., additional, Kastrup, Jens, additional, Fernández-Avilés, Francisco, additional, Sanz-Ruiz, Ricardo, additional, Mathur, Anthony, additional, Wojakowski, Wojcieh, additional, Martin-Rendon, Enca, additional, Pavo, Noemi, additional, Pavo, Imre J., additional, Hemetsberger, Rayyan, additional, Traxler, Denise, additional, Spannbauer, Andreas, additional, and Haller, Paul M., additional

Published
2022
Full Text
View/download PDF

36. Long-Term Suppression of Atrial Fibrillation by Botulinum Toxin Injection into Epicardial Fat Pads in Patients Undergoing Cardiac Surgery: One Year Follow Up of a Randomized Pilot Study

Author

Pokushalov, Evgeny, Kozlov, Boris, Romanov, Alexander, Strelnikov, Artem, Bayramova, Sevda, Sergeevichev, David, Bogachev-Prokophiev, Alexander, Zheleznev, Sergey, Shipulin, Vladimir, Lomivorotov, Vladimir V., Karaskov, Alexander, Po, Sunny S., and Steinberg, Jonathan S.

Published
2015
Full Text
View/download PDF

42. B-PO05-179 A NEW CLINICAL DECISION SUPPORT TOOL BASED ON PERSONALIZED EVIDENCE-BASED MEDICINE IMPROVES OUTCOMES OF ANTICOAGULATION THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION: AN ANALYSIS FROM THE ATRIAL FIBRILLATION REGISTRY

Author

Pokushalov, Evgeny A., primary, Losik, Denis, additional, Kozlova, Svetlana, additional, Konradi, Alexandra, additional, Sekacheva, Marina, additional, Ponomarenko, Andrey, additional, Krivosheev, Yuri, additional, Mikheenko, Igor, additional, Kretov, Evgeny, additional, and Steinberg, Jonathan S., additional

Published
2021
Full Text
View/download PDF

43. B-PO01-075 ASSOCIATION BETWEEN PERSONALIZED EVIDENCE-BASED ANTICOAGULATION THERAPY AND OUTCOMES AT 1-YEAR FOLLOW-UP IN PATIENTS WITH ATRIAL FIBRILLATION: AN ANALYSIS FROM THE ATRIAL FIBRILLATION REGISTRY

Author

Pokushalov, Evgeny A., primary, Losik, Denis, additional, Kozlova, Svetlana, additional, Konradi, Alexandra, additional, Sekacheva, Marina, additional, Ponomarenko, Andrey, additional, Krivosheev, Yuri, additional, Mikheenko, Igor, additional, Kretov, Evgeny, additional, and Steinberg, Jonathan S., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results